Ultra-Deep Massive Parallel Sequencing of Plasma Cell-Free DNA Enables Large-Scale Profiling of Driver Mutations in Vietnamese Patients With Advanced Non-Small Cell Lung Cancer
Autor: | Luan Thanh Nguyen, Hai-Ha Bui, Chu Van Nguyen, Ha Thu Le, Thai-Hoa Thi Nguyen, Lam-Son Pham, Thanh-Thanh Thi Nguyen, Thanh-Thuy Thi Do, Kim-Huong Thi Nguyen, Yen-Vi Vu, Vinh-Quang Bui, Anh-Thu Huynh Dang, Hoa Giang, Le Son Tran, Vu Thuong Le, Thanh-Truong Tran, Quynh-Tho Thi Nguyen, Nguyen Huu Nguyen, Binh Thanh Vo, Long Hung Nguyen, Minh-Duy Phan, Hoai-Nghia Nguyen, Kiet Truong Dinh, Hong-Anh Thi Pham, Vu-Uyen Tran, Thien-Chi Van Nguyen, Nien Vinh Lam, Mai-Lan Thi Nguyen |
---|---|
Rok vydání: | 2020 |
Předmět: |
ultra-deep sequencing
0301 basic medicine Cancer Research medicine.medical_treatment actionable mutations Population Biology lcsh:RC254-282 Genetic analysis tissue biopsy Targeted therapy 03 medical and health sciences 0302 clinical medicine medicine Liquid biopsy education Lung cancer Gene non-small cell lung cancer Original Research circulating tumor DNA education.field_of_study Massive parallel sequencing liquid biopsy business.industry targeted therapy lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer research Personalized medicine business |
Zdroj: | Frontiers in Oncology, Vol 10 (2020) Frontiers in Oncology |
ISSN: | 2234-943X |
Popis: | Population-specific profiling of mutations in cancer genes is of critical importance for the understanding of cancer biology in general as well as the establishment of optimal diagnostics and treatment guidelines for that particular population. Although genetic analysis of tumor tissue is often used to detect mutations in cancer genes, the invasiveness and limited accessibility hinders its application in large-scale population studies. Here, we used ultra-deep massive parallel sequencing of plasma cell free DNA (cfDNA) to identify the mutation profiles of 265 Vietnamese patients with advanced non-small cell lung cancer (NSCLC). Compared to a cohort of advanced NSCLC patients characterized by sequencing of tissue samples, cfDNA genomic testing, despite lower mutation detection rates, was able to detect major mutations in tested driver genes that reflected similar mutation composition and distribution pattern, as well as major associations between mutation prevalence and clinical features. In conclusion, ultra-deep sequencing of plasma cfDNA represents an alternative approach for population-wide genetic profiling of cancer genes where recruitment of patients is limited to the accessibility of tumor tissue site. |
Databáze: | OpenAIRE |
Externí odkaz: |